Tagrisso 80 mg Tablets contain Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI). It is primarily used for treating non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M-positive and exon 19 deletions or exon 21 (L858R) substitutions. Tagrisso is indicated both as first-line therapy and for patients whose cancer has progressed following prior EGFR-TKI treatment.

• Targets specific EGFR mutations, including T790M resistance mutation

• Shown to delay disease progression and extend overall survival

• Penetrates the blood-brain barrier, helping control brain metastases

• Oral, once-daily dosing improves patient compliance

• Used in adjuvant settings after tumor resection in early-stage lung cancer

• Take one tablet (80 mg) once daily

• Can be taken with or without food

• Swallow the tablet whole with water; do not crush or split

• Take at the same time each day for consistent blood levels

• Follow your oncologist’s instructions strictly

• Active Ingredient: Osimertinib 80 mg

• Standard Dose: 80 mg orally once daily

• Duration of therapy depends on treatment response and tolerability

• No dose adjustment typically required for mild to moderate kidney/liver impairment

• Contraindicated in patients with known hypersensitivity to Osimertinib

• Caution in patients with interstitial lung disease, cardiac conditions, or eye disorders

• Avoid use during pregnancy and breastfeeding

• Regular monitoring of heart function (QT prolongation) and lung imaging is recommended

• Inform your doctor about any other prescription, OTC drugs, or supplements

Common Side Effects:

• Diarrhea

• Rash or dry skin

• Nail disorders

• Decreased appetite

• Fatigue

Serious Side Effects:

• Interstitial lung disease (ILD)

• QT prolongation (irregular heartbeat)

• Cardiomyopathy (heart dysfunction)

• Eye problems (blurred vision, keratitis)

• Blood abnormalities (low white cells, platelets)

• Store at 20°C to 25°C (68°F to 77°F)

• Keep in original packaging to protect from moisture

• Keep away from children and pets

• Do not use after expiration date

Q1: Who should take Tagrisso?
Tagrisso is prescribed to patients with EGFR-mutated NSCLC, especially those with the T790M mutation or as first-line therapy.

Q2: Can I take Tagrisso with other cancer drugs?
Only if approved by your oncologist. Tagrisso can interact with certain other medications.

Q3: How long should I take Tagrisso?
Treatment is typically continued until disease progression or unacceptable side effects occur.

Q4: What if I miss a dose?
If less than 12 hours have passed, take it as soon as remembered. If more than 12 hours, skip the dose and take the next one at the usual time.

Q5: Is there a way to test if Tagrisso will work for me?
Yes. EGFR mutation testing is done on tumor tissue or blood to determine eligibility.